Article
TET2 binds the androgen receptor and loss is associated with prostate cancer.
Oncogene - 1 Apr 2017
Nickerson M L, Das S, Im K M, Turan S, Berndt S I, Li H, Lou H, Brodie S A, Billaud J N, Zhang T, Bouk A J, Butcher D, Wang Z, Sun L, Misner K, Tan W, Esnakula A, Esposito D, Huang W Y, Hoover R N, Tucker M A, Keller J R, Boland J, Brown K, Anderson S K, Moore L E, Isaacs W B, Chanock S J, Yeager M, Dean M, Andresson T
Abstract excerpt
Genetic alterations associated with prostate cancer (PCa) may be identified by sequencing metastatic tumour genomes to identify molecular markers at this lethal stage of disease. Previously, we characterized somatic alterations in metastatic tumours in the methylcytosine dioxygenase ten-eleven translocation 2 (TET2), which is altered in 5-15% of myeloid, kidney, colon and PCas. Genome-wide association studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.